Literature DB >> 837550

Micro-scale method for theophylline in body fluids by reversed-phase, high-pressure liquid chromatography.

J J Orcutt, P P Kozak, S A Gillman, L H Cummins.   

Abstract

We describe a micro-scale method for determining serum theophylline. The chromatography system includes a muBondapack C18 column and acetonitrile, 70 ml/liter of sodium acetate buffer (10 mmol/liter, ph 4.0) as the mobile phase. Test serum or plasma, 30 mul, is mixed with an equal quantity of a solution containing the internal standard, beta-hydroxyethyltheophylline in acetonitrile/sodium acetate buffer (20 mmol/liter, pH 4.0), 7/43 by vol. After the precipitate is removed by centrifugation, the mixture is chromatographed and the amount of theophylline calculated from the ratio between peak heights for theophylline and the internal standard. Advantages include easy sample preparation, involving only addition of internal standard and centrifugation before injection, long column life, and the suitability of the internal standard, which is adjusted to a peak height equivalent to 20 mg of theophylline per liter for easy computation of results.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837550

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  30 in total

1.  Theophylline steady state pharmacokinetics is not altered by omeprazole.

Authors:  A M Taburet; J Geneve; M Bocquentin; G Simoneau; C Caulin; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Is diurnal variation in absorption of slow-release aminophylline an age-related phenomenon?

Authors:  A Rodgers; D N Bateman; K W Woodhouse
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Lowering of theophylline clearance by isoniazid in slow and rapid acetylators.

Authors:  B Santoso
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

4.  Diurnal variation in the pharmacokinetics of intravenous theophylline and etophylline in healthy subjects.

Authors:  B L Chauhan; B S Doshi; R D Kulkarni
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Accumulation of caffeine in healthy volunteers treated with furafylline.

Authors:  E Tarrus; J Cami; D J Roberts; R G Spickett; E Celdran; J Segura
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

Review 6.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

7.  Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.

Authors:  Z Hussein; M Friedman
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

8.  The influence of antacid on the absorption of two different sustained-release formulations of theophylline.

Authors:  K I Myhre; R A Walstad
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

9.  Effect of phenobarbital on serum and biliary parameters in a patient with Crigler-Najjar syndrome, type II and acquired cholestasis.

Authors:  B W Trotman; L Shaw; J Roy-Chowdhury; P F Malet; E F Rosato
Journal:  Dig Dis Sci       Date:  1983-08       Impact factor: 3.199

10.  Renal clearance of theophylline and its major metabolites: age and urine flow dependency in paediatric patients.

Authors:  I Bonnacker; D Berdel; R Süverkrüp; A von Berg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.